Has Anita Kablinger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $57,350 in general payments to Anita Kablinger, MD across 35 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anita Kablinger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anita Kablinger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anita Kablinger, MD

Psychiatry · Roanoke, VANPI 1104859214

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $54,594 of the $57,350 with a category attached, or 95.2%. Gilead accounts for 95.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $20,763 and has fallen 97.9% since, to $437 in 2025. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,350in general payments, 2019–2025

Across 35 payments — averaging $1638.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$55K
Livanova USA, Inc.$673
Neurocrine Biosciences, Inc.$414
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$411
Teva Pharmaceuticals USA, Inc.$295
Johnson & Johnson$275
plus $689 from 6 others

$275,506in research payments, 2019–2025

Across 208 payments — averaging $1324.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Livanova USA, Inc.$234K
AbbVie$19K
Genentech, Inc.$13K
Sunovion Pharmaceuticals Inc.$9K
Pfizer$1K

What the payments were for

Consulting fees$54,59495%
Food & beverage$2,7575%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	6	$54,594
Livanova USA, Inc.	7	$673
Neurocrine Biosciences, Inc.	5	$414
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	5	$411
Teva Pharmaceuticals USA, Inc.	3	$295
Johnson & Johnson	2	$275
AbbVie	2	$227
Vanda Pharmaceuticals Inc.	1	$124
Sunovion Pharmaceuticals Inc.	1	$115
E.r. Squibb & Sons, L.L.C.	1	$96
Axsome Therapeutics, Inc.	1	$95
Janssen Scientific Affairs, LLC	1	$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VNS Therapy Symmetry Model 8103 Generator$370
CAPLYTA$340
SPRAVATO$275
Fanapt$124
UZEDY$118
LATUDA$115
VRAYLAR$115
Mavyret$113
INGREZZA$110

How this compares

$57,350 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia →

Medicare billing

Part B allowed, 2024

$13,744

Medicare patients

Services billed

170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VyvanseLisdexamfetamine Dimesylate	11	$3,963
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	14	$844
Bupropion XlBupropion Hcl	28	$512
Duloxetine Hcl	14	$235
Clonazepam	31	$227
Buspirone Hcl	11	$169
Gabapentin	11	$126
Escitalopram Oxalate	23	$124
Alprazolam	18	$112
Zolpidem Tartrate	11	$35

Paid to pharmacies, not to this prescriber.

Other psychiatry in Roanoke

David ScheidererRoanoke$2.4M
Ralph McKenzieRoanoke$161K
Roopa SethiRoanoke$9K
Niku SinghFalls Church$2.5M
Kent McDanielGlen Allen$2.1M
Jasdeep MiglaniManassas$958K
David SpiegelNorfolk$565K
William YetterVirginia Beach$312K
Anita ClaytonCharlottesville$260K
Robert GardellaStaunton$201K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →